Search results for : vegf - Cancerrxgene - Genomics of Drug Sensitivity in Cancer

Search Results for: vegf

Drugs (17)

Name	Synonyms	Targets	Target Pathway	PubCHEM	Datatset	Sample size	Screening site
Axitinib	AG-13736, Inlyta	PDGFR, KIT, VEGFR	RTK signaling	6450551	GDSC1	927	SANGER
Axitinib	AG-13736, Inlyta	PDGFR, KIT, VEGFR	RTK signaling	6450551	GDSC2	961	SANGER
BIBF-1120		VEGFR, PDGFR, FGFR	RTK signaling		GDSC1	918	MGH
Brivanib, BMS-540215		VEGFR, PDGFR	RTK signaling		GDSC1	918	MGH
Cabozantinib	BMS-907351, XL-184, Cometriq	VEGFR, MET, RET, KIT, FLT1, FLT3, FLT4, TIE2,AXL	RTK signaling	25102847	GDSC1	911	MGH
Cediranib	AZD2171, AZD 2171, AZD-2171, Recentin	VEGFR, FLT1, FLT2, FLT3, FLT4, KIT, PDGFRB	RTK signaling	9933475	GDSC2	958	SANGER
Foretinib	GSK1363089, XL-880, EXEL-2880, GSK089	MET, KDR, TIE2, VEGFR3/FLT4, RON, PDGFR, FGFR1, EGFR	RTK signaling	42642645	GDSC1	909	MGH
Foretinib	GSK1363089, XL-880, EXEL-2880, GSK089	MET, KDR, TIE2, VEGFR3/FLT4, RON, PDGFR, FGFR1, EGFR	RTK signaling	42642645	GDSC2	953	SANGER
Linifanib	ABT-869, ABT 869	VEGFR1, VEGFR2, VEGFR3, CSF1R, FLT3, KIT	RTK signaling	11485656	GDSC1	914	MGH
Motesanib	AMG-706, AMG 706, AMG706	VEGFR, RET, KIT, PDGFR	RTK signaling	11667893	GDSC1	927	SANGER
Motesanib	AMG-706, AMG 706, AMG706	VEGFR, RET, KIT, PDGFR	RTK signaling	11667893	GDSC2	949	SANGER
OSI-930	OSI 930 OSI930	KIT, VEGFR2	RTK signaling	9868037	GDSC1	913	MGH
Ponatinib	AP24534, AP-24534, KIN001-192, Iclusig	ABL, PDGFRA, VEGFR2, FGFR1, SRC, TIE2, FLT3	Other, kinases	24826799	GDSC1	877	MGH
Sorafenib	Nexavar, 284461-73-0, BAY 43-9006	PDGFR, KIT, VEGFR, RAF	RTK signaling	216239	GDSC1	396	MGH
Sorafenib	Nexavar, 284461-73-0, BAY 43-9006	PDGFR, KIT, VEGFR, RAF	Other, kinases	216239	GDSC2	958	SANGER
Sunitinib	Sutent, Sunitinib Malate, SU-11248	PDGFR, KIT, VEGFR, FLT3, RET, CSF1R	RTK signaling	5329102	GDSC1	396	MGH
Tivozanib	AV-951, AV 951, KRN-951, KIL8951, ASP-4130	VEGFR1, VEGFR2, VEGFR3, PDGFR, KIT	RTK signaling	9911830	GDSC1	912	MGH

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).